Acumen Pharmaceuticals Inc

NASDAQ ABOS

Download Data

Acumen Pharmaceuticals Inc Net Working Capital to Total Assets Ratio 3 year CAGR for the year ending December 31, 2023: -4.19%

Acumen Pharmaceuticals Inc Net Working Capital to Total Assets Ratio 3 year CAGR is -4.19% for the year ending December 31, 2023, a -228.63% change year over year. The net working capital to total assets ratio measures the proportion of a company's net working capital (current assets minus current liabilities) to its total assets. It is calculated by dividing the net working capital by the total assets. This ratio indicates the percentage of a company's total assets that are financed by its net working capital. A higher ratio suggests a greater reliance on working capital to fund the company's operations and indicates a potential liquidity cushion. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Acumen Pharmaceuticals Inc Net Working Capital to Total Assets Ratio for the year ending December 31, 2022 was 0.88, a 4.45% change year over year.
  • Acumen Pharmaceuticals Inc Net Working Capital to Total Assets Ratio for the year ending December 31, 2021 was 0.84, a -1.93% change year over year.
  • Acumen Pharmaceuticals Inc Net Working Capital to Total Assets Ratio for the year ending December 31, 2020 was 0.86, a 7.48% change year over year.
  • Acumen Pharmaceuticals Inc Net Working Capital to Total Assets Ratio for the year ending December 31, 2019 was 0.80.
NASDAQ: ABOS

Acumen Pharmaceuticals Inc

CEO Mr. Daniel J. O'Connell M.B.A.
IPO Date July 1, 2021
Location United States
Headquarters 427 Park Street, Charlottesville, VA, United States, 22902
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email